Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty liver disease, especially in women and men who are 50 years old and younger.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup